Connection

Co-Authors

This is a "connection" page, showing publications co-authored by IAN E MCCUTCHEON and JOHN M SLOPIS.
Connection Strength

1.259
  1. A Massive Thoracic Meningocele in a Patient with NF1. Can J Neurol Sci. 2024 Oct 03; 1.
    View in: PubMed
    Score: 0.248
  2. Surgical treatment of common peroneal neuropathy in schwannomatosis: illustrative cases. J Neurosurg Case Lessons. 2021 Jun 28; 1(26):CASE21176.
    View in: PubMed
    Score: 0.198
  3. Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg. 2018 09; 129(3):805-814.
    View in: PubMed
    Score: 0.152
  4. Neurofibromas of the Phrenic Nerve: A Case Report and Review of the Literature. World Neurosurg. 2016 Apr; 88:237-242.
    View in: PubMed
    Score: 0.135
  5. Therapeutic Strategies for Gliomas Associated With Cancer Predisposition Syndromes. JCO Precis Oncol. 2024 Feb; 8:e2300442.
    View in: PubMed
    Score: 0.059
  6. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest. 2022 06; 102(6):658-666.
    View in: PubMed
    Score: 0.052
  7. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.050
  8. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021 03 01; 4(3):e210945.
    View in: PubMed
    Score: 0.048
  9. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019 01; 25(1):176-187.
    View in: PubMed
    Score: 0.042
  10. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg. 2017 Jan; 126(1):319-329.
    View in: PubMed
    Score: 0.034
  11. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther. 2016; 17(2):129-38.
    View in: PubMed
    Score: 0.034
  12. Multidetector CT with 3-dimensional volume rendering in the evaluation of the spine in patients with Neurofibromatosis type 1: a retrospective review in 73 patients. Scoliosis. 2014; 9:15.
    View in: PubMed
    Score: 0.031
  13. The value of ?8F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. 2014 Sep; 41(9):1756-66.
    View in: PubMed
    Score: 0.030
  14. Binding partners for curcumin in human schwannoma cells: biologic implications. Bioorg Med Chem. 2013 Feb 15; 21(4):932-9.
    View in: PubMed
    Score: 0.027
  15. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8.
    View in: PubMed
    Score: 0.026
  16. Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways. Mol Cancer Ther. 2011 Nov; 10(11):2094-103.
    View in: PubMed
    Score: 0.025
  17. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011 Jan 01; 71(1):185-96.
    View in: PubMed
    Score: 0.024
  18. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009 Jun; 249(6):1014-22.
    View in: PubMed
    Score: 0.021
  19. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.